- Available Alternative Biologics and Disease Groups Influence Biologic Drug Survival in Patients with Psoriasis and Psoriatic Arthritis
-
Oh S, Choi S, Yoon HS
- KMID: 2533604
- Ann Dermatol.
- 2022 Oct;34(5):321-330.
- doi: 10.5021/ad.22.003
Background: Factors other than efficacy and safety could influence the survival of biologics in patients with psoriasis. Little is known about whether different disease groups affect drug survival of biologics... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
-
Shin SY, Park SJ, Kim Y, Im JP, Kim HJ, Lee KM, Kim JW, Jung SA, Lee J, Kang SB, Shin SJ, Kim ES, Kim YS, Kim TO, Kim HS, Park DI, Kim HK, Kim ES, Kim YH, Kim DH, Teng D, Kim JH, Kim W, Choi CH, on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases
- KMID: 2531989
- Intest Res.
- 2022 Jul;20(3):350-360.
- doi: 10.5217/ir.2021.00049
Background/Aims: This study assessed the efficacy and safety of adalimumab (ADA) and explored predictors of response in Korean patients with ulcerative colitis (UC). Methods: A prospective, observational, multicenter study was conducted... -
- CITED
-
- Close
- SHARE
-
- Close
- Real-World Incidence of Suboptimal Response to Anti-Tumor Necrosis Factor Therapy for Ulcerative Colitis: A Nationwide Population-Based Study
-
Shin JY, Park HM, Lee MY, Jeon JY, Yoo HJ, Ye BD
- KMID: 2522348
- Gut Liver.
- 2021 Nov;15(6):867-877.
- doi: 10.5009/gnl20353
Background/Aims: Although anti-tumor necrosis factor (TNF) agents have been widely used to treat ulcerative colitis (UC), the real-world incidence of suboptimal response to anti-TNF agents has not been thoroughly investigated,... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study
-
Song JH, Kang EA, Park SK, Hong SN, Kim YS, Bang KB, Kim KO, Lee HS, Kang SB, Shin SY, Song EM, Im JP, Choi CH, Group of the Korean Association for the Study of Intestinal Diseases
- KMID: 2520127
- Gut Liver.
- 2021 Sep;15(5):752-762.
- doi: 10.5009/gnl20233
Background/Aims: Our study aimed to evaluate the long-term outcomes and risk factors for relapse after anti-tumor necrosis factor (TNF)-α cessation in inflammatory bowel disease (IBD) patients because they are not well... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy
-
Kim J, Im JP, Yim JJ, Lee CK, Park DI, Eun CS, Jung SA, Shin JE, Lee KM, Cheon JH
- KMID: 2471137
- Korean J Gastroenterol.
- 2020 Jan;75(1):29-38.
- doi: 10.4166/kjg.2020.75.1.29
BACKGROUND/AIMS: Anti-tumor necrosis factor (TNF) therapy is used widely for the treatment of inflammatory bowel disease (IBD). In the present study, the characteristics and outcomes of tuberculosis (TB) in IBD... -
- CITED
-
- Close
- SHARE
-
- Close
- Review of Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis
-
Song JS
- KMID: 2202185
- J Korean Rheum Assoc.
- 2007 Mar;14(1):1-14.
- doi: 10.4078/jkra.2007.14.1.1
Advanced knowledges of cellular and molecular biology led to the development of therapies of rheumatoid arthritis (RA). The introduction of biologic agents into clinical practice has had a profound effect... -
- CITED
-
- Close
- SHARE
-
- Close
